Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Cited by (1,007)

Items 801–900 of 1,007

1. Population-based study of the durability of humoral immunity after SARS-CoV-2 infection
   David Peterhoff, Simon Wiegrebe, Sebastian Einhauser, Arisha Johanna Patt, Stephanie Beileke, Felix Günther, Philipp A. Steininger, Hans Helmut Niller, Ralph Burkhardt, Helmut Küchenhoff et al. · 2023 · Frontiers in Immunology
2. Multicentric evaluation of sensitivity of eight commercial anti-SARS-CoV-2 antibody assays and their correlation to virus neutralization titers in seropositive subjects
   Miroslav Fajfr, Petr Pajer, Daniel Růžek, Radek Sleha, Sylva Janovská, Miloš Bohoněk, Hana Kabíčková, Pavla Kubíčková, Michal Štefánik, Petra Straková et al. · 2024 · Scientific Reports
3. Sex‐specific disparities in COVID‐19 outcomes
   Zubaid Rafique, Valerie L. Durkalski‐Mauldin, W. Frank Peacock, Kabir Yadav, Joshua C. Reynolds, Clifton W. Callaway · 2024 · Journal of the American College of Emergency Physicians Open
4. The omicron variant of SARS-CoV-2 drove broadly increased seroprevalence in a public university setting
   Ching‐Wen Hou, Stacy Williams, Guillermo Sebastian Triviño Soto, Veronica Boyle, David Rainford, Selina Vicino, Mitch Magee, Yunro Chung, Joshua LaBaer, Vel Murugan · 2025 · PLOS Global Public Health
5. Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection
   Carla Martín Pérez, Anna Ramírez‐Morros, Alfons Jiménez, Marta Vidal, Edwards Pradenas, Diana Barrios, Mar Canyelles, Rocío Rubio, Inocência Cuamba, Luís Izquierdo et al. · 2025 · Communications Medicine
6. Healthcare worker protection against epidemic viral respiratory disease
   Yarrow Scantling‐Birch, Richard Newton, Hasan Naveed, Saul N Rajak, Mahmood Fazal Bhutta · 2021 · Postgraduate Medical Journal
7. SARS-CoV-2 infection in general practice in Ireland: a seroprevalence study
   Michael Edmund O’Callaghan, Elizabeth J. Ryan, Cathal Walsh, Peter Hayes, Monica Casey, Pat O’Dwyer, Aidan Culhane, John W Duncan, Pat Harrold, Jarlath Healy et al. · 2021 · BJGP Open
8. Symptoms, antibody levels and vaccination attitude after asymptomatic to moderate COVID-19 infection in 200 healthcare workers
   Igor Alexander Harsch, Andrea Ortloff, Mike Reinhöfer, Jörg Epstude · 2021 · PubMed Central
9. Identifying Inconclusive Data in the SARS-CoV-2 Molecular Diagnostic Using Nucleocapsid Phosphoprotein Gene as a Target
   Raphael Contelli Klein, Mary Hellen Fabres Klein, Larissa Gomes Barbosa, Lívia Vasconcelos Gonzaga Knnup, Larissa Paola Rodrigues Venâncio, Jonilson Berlink Lima, Théo Araújo-Santos · 2021 · Archives of Pathology & Laboratory Medicine
10. Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19
    Eberhard Wieland · 2021 · Therapeutic Drug Monitoring
11. SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests
    Grant A. Kay, Sophie I. Owen, Emanuele Giorgi, David J. Clark, Christopher T. Williams, Stefanie K. Menzies, Luís E. Cuevas, Benedict M O Davies, Nicholas M Eckersley, Grant L. Hughes et al. · 2022 · Scientific Reports
12. Long-term immune responses in patients with confirmed novel coronavirus disease-2019: a 9-month prospective cohort study in Shanghai, China
    Xiaohuan Gong, Peng Cui, Huanyu Wu, Hào Pān, Zheng Teng, Fang Yuan, Shenghua Mao, Dechuan Kong, Ruobing Han, Xue Zhao et al. · 2022 · BMC Infectious Diseases
13. COVID-19: Current Challenges and Future Perspectives
    Leggat, Peter, Frean, John, Blumberg, Lucille · 2022 · MDPI eBooks
14. Optimal policies for mitigating pandemic costs: a tutorial model
    Mattia Serra, Salem al-Mosleh, S Ganga Prasath, V Raju, Sreekar Mantena, Jay Chandra, Sarah Iams, L. Mahadevan · 2022 · Physical Biology
15. Impact of SARS-CoV-2-specific memory B cells on the immune response after mRNA-based Comirnaty vaccine in seronegative health care workers
    Alejandro Vallejo, Pilar Vizcarra, Adrián Martín-Hondarza, Sandra Gómez-Maldonado, Johannes Häemmerle, Héctor Velasco, José L. Casado · 2022 · Frontiers in Microbiology
16. Long-Term Effects of COVID-19 on Lungs and the Clinical Relevance: A 6-Month Prospective Cohort Study
    Gülşah Tunçer, Ceyda Geyiktepe-Güçlü, Serkan Sürme, Evren Canel Karakas, Hatice Erdogan, Osman Faruk Bayramlar, Cansu Belge, Rıdvan Karahasanoğlu, Betül Çopur, Meltem Yazla et al. · 2023 · Future Microbiology
17. What contributes to the re-positive nucleic acid test results for the omicron variant of SARS-CoV-2 in the shelter cabin hospital in Shanghai, China?
    Mei Peng, Maozi Hu, Xiaolu Peng, Yuan Gong, Keli Qian, Junnan Li, Jinqiu Zhao, Xiang Li, Jing Yang Huang, Meng Zhang et al. · 2023 · Heliyon
18. To be remembered: B cell memory response against SARS‐CoV ‐2 and its variants in vaccinated and unvaccinated individuals
    Nafees Ahmed, Atharv Athavale, Ankita Harishchandra Tripathi, Adarsh Subramaniam, Santosh Kumar Upadhyay, Anil Kumar Pandey, Ramesh Chandra Rai, Amit Awasthi · 2023 · Scandinavian Journal of Immunology
19. A Comprehensive Study of Cellular and Humoral Immunity in Dogs Naturally Exposed to SARS‐CoV‐2
    Beatriz Davinia Tomeo-Martín, Pablo Delgado-Bonet, Teresa Cejalvo, Sandra Herranz, Ana Judith Perisé-Barrios · 2024 · Transboundary and Emerging Diseases
20. Effect of thymalin on adaptive immunity in complex therapy for patients with COVID-19
    Vladimir Kh. Khavinson, Kuznik Bi, Volchkov Va, Светлана Александровна Рукавишникова, O. N. Titova, Ахмедов Тимур Артыкович, S. V. Trofimova, Galina Anatol’evna Ryzhak, Vitaly V. Potyomkin, Урал Ринатович Сагинбаев · 2021 · Clinical Medicine (Russian Journal)
21. Convalescent Plasma: An Evidence-Based Old Therapy to Treat Novel Coronavirus Patients
    Saurabh Kumar, Chandra Devi, Subhabrata Sarkar, Vivek Kumar Garg, Priyanka Choudhary, Madhu Chopra, Vinit Sharma, Ravi Prakash · 2021 · IntechOpen eBooks
22. Langzeitpflegeeinrichtungen in der COVID-19-Pandemie
    Markus Gosch, D. Altrichter, M. Pflügner, Helmut Frohnhofen, Jörg Steinmann, I. Schmude-Basic, A. Adamek, I. Johnscher, Ulla Kandler, Christina Wunner et al. · 2021 · Zeitschrift für Gerontologie und Geriatrie
23. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion
    Oliver Fabian Wirz, Katharina Röltgen, Bryan Stevens, Suchitra Pandey, Malaya Kumar Sahoo, Lorna L. Tolentino, Michelle Verghese, Khoa D. Nguyen, Molly Hunter, Theo Thomas Snow et al. · 2021 · Frontiers in Immunology
24. A surrogate cell‐based SARS‐CoV‐2 spike blocking assay
    Wolfgang Schuh, Lena Baus, Tobit D. Steinmetz, Sebastian R. Schulz, Leonie Weckwerth, Edith A. Roth, Manuela Hauke, Sara K. Krause, Patrick Morhart, Manfred Rauh et al. · 2021 · European Journal of Immunology
25. Humoral Response of Patients With Autoimmune Rheumatic Disease to BNT162b2 Vaccine: A Retrospective Comparative Study
    Omar Suhail Alsaed, Samar Al Emadi, Eman Satti, Bassam Muthanna, Safna Farsana Akkam Veettil, Hadeel Ashour, Prem Chandra, Einas Al‐Kuwari, Peter Valentine Coyle · 2022 · Cureus
26. Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity
    Kalyan Pande, Scott A. Hollingsworth, Miranda Sam, Qinshan Gao, Sujata Singh, Anasuya Saha, Karin Vroom, Xiaohong Shirley, Tres Brazell, Dan Gorman et al. · 2022 · Frontiers in Immunology
27. SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol
    Vivienne C. Bachelet, Ignacio Silva-Ayarza, Francisca J Lizana, Patricio Gomolan G., Diego Silva-Villalobos, María Soledad Navarrete · 2022 · BMJ Open
28. Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection
    Laura Serrano, Sonia Algarate, Beatriz Herrero‐Cortina, Jessica Bueno, María T. González-Barriga, María Ducons, Jesica Montero‐Marco, Beatriz Acha, Ana Taboada, Pilar Sanz-Burillo et al. · 2022 · Journal of Applied Microbiology
29. Association of Results of Four Lateral Flow Antibody Tests with Subsequent SARS-CoV-2 Infection
    Lucy Findlater, Adam Trickey, Hayley E. Jones, Amy Trindall, Sian Taylor‐Phillips, Ranya Mulchandani, EDSAB-HOME investigators, Isabel Oliver, D H Wyllie · 2022 · Microbiology Spectrum
30. Seroprevalence of SARS-CoV-2 antibodies in vaccinated healthcare workers in Marrakech (Morocco)
    Taoufik Ben Houmich, Abdelali Tali, Debbagh Fayrouz, Asma Lamrani Hanchi, Nabila Soraa · 2022 · International Journal of Immunopathology and Pharmacology
31. Serology Testing Demonstrates That Antibodies to SARS-CoV-2 S1-RBD Correlate with Neutralization of Virus Infection of Vero E6 Cells
    James Freeman, Justin Conklin, Diana Oramus, Kelly A. Cycon · 2021 · The Journal of Applied Laboratory Medicine
32. Optimizing SARS-CoV-2 molecular diagnostic using N gene target: insights about reinfection
    Raphael Contelli Klein, Mary Hellen Fabres Klein, Larissa Gomes Barbosa, Lívia de Vasconcellos Gonzaga Knupp, Larissa Paola Rodrigues Venâncio, Jonilson Berlink Lima, Théo Araújo-Santos · 2020 · medRxiv
33. Impact of booster COVID-19 vaccine for Moroccan adults: A discrete age-structured model approach
    Aayah Hammoumi, Hanane Hmarrass, Redouane Qesmi · 2021 · medRxiv
34. Neutralization of VOCs including Delta one year post COVID-19 or vaccine
    Sebastian Havervall, Ulrika Wimmercranz Marking, Max Gordon, Henry Ng, Nina Greilert‐Norin, Sarah Lindbo, Kim G. Blom, Peter Nilsson, Mia Phillipson, Jonas Klingström et al. · 2021 · medRxiv
35. Anti-nucleocapsid antibody levels reflect post-acute sequelae of COVID-19 symptom burden in children
    Pei‐Chi Chen, Yu‐Lung Hsu, Chih‐Yu Lin, Xiaoling Liu, Miao-Hsi Hsieh, Hui‐Ju Tsai, Wen‐Shuo Kuo, Hui-Fang Kao, Shulhn-Der Wang, Yung‐Jen Ho et al. · 2025 · Journal of Infection and Public Health
36. Intranasal DC-targeting vaccine booster elicits durable and cross-clade protective immunity against sarbecoviruses in mice
    Nicholas You Zhi Cheang, Wee Chee Yap, Kirsteen McInnes Tullett, Xinlei Qian, Peck Szee Tan, Kiren Purushotorman, Wan Yi Tan, Shirley Yun Yan Mah, Paul A. MacAry, Chee Wah Tan et al. · 2026 · Journal of Clinical Investigation
37. Down but far from out: The durability of SARS-CoV-2 immunity after asymptomatic infection
    Ross M. Kedl · 2021 · The Journal of Experimental Medicine
38. Real-world performance of SARS-Cov-2 serology tests in the United States, 2020
    Carla Rodriguez‐Watson, Anthony M. Louder, Carly A. Kabelac, Christopher M. Frederick, Natalie E. Sheils, Elizabeth H. Eldridge, Nancy D. Lin, Benjamin D. Pollock, Jennifer L. Gatz, Shaun J. Grannis et al. · 2023 · PLoS ONE
39. Performance of T-Track® SARS-CoV-2, an Innovative Dual Marker RT-qPCR-Based Whole-Blood Assay for the Detection of SARS-CoV-2-Reactive T Cells
    Franziska M. Kanis, Johannes P. Meier, Harald Guldan, Hans-Helmut Niller, Michael Dahm, Alexander Dansard, Thomas Zander, Friedhelm Struck, Erwin Soutschek, Ludwig Deml et al. · 2023 · Diagnostics
40. Longitudinal anti-SARS-CoV-2 antibody immune response in acute and convalescent patients
    Horacio Pérez-Juárez, Angélica Serrano-Vázquez, Héctor Godínez–Álvarez, Enrique González, Liliana Rojas-Velázquez, Patricia A. Moran, Tobías Portillo-Bobadilla, Manuel H Ramiro, Eric Hernández, Clara Bik‐San Lau et al. · 2023 · Frontiers in Cellular and Infection Microbiology
41. Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023
    Huan Zhang, Baisheng Li, Jiufeng Sun, Lirong Zou, Lina Yi, Huifang Lin, Pingping Zhou, Chumin Liang, Lilian Zeng, Xue Zhuang et al. · 2024 · Virology Journal
42. Vitamin D as an Adjuvant Immune Enhancer to SARS-Cov-2 Vaccine
    Azza Salamony, Maha Abdelsalam, Nancy Elguindy, W. Roshdy, Amr Youssef, Yara I Shamikh · 2025 · Current Microbiology
43. Protective Potential and Functional Role of Antibodies Against SARS-CoV-2 Nucleocapsid Protein
    Alexandra Ya. Rak, Ekaterina A. Bazhenova, Прокопенко Полина Игоревна, Victoria Matyushenko, Yana R. Orshanskaya, К. В. Сивак, Костромитина Арина Дмитриевна, Руденко Лариса Георгиевна, Irina Isakova-Sivak · 2025 · Antibodies
44. Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern
    Khursheed Ul Islam, Thoraya Mohamed Elhassan A-Elgadir, Sarah Afaq, Tanveer Ahmad, Jawed Iqbal · 2021 · Frontiers in Pharmacology
45. COVID-19: A Systematic Review of the Transmissibility, Pathogenesis, Entry Factors, and Signature Immune Response
    Deena Fayyad, Jessica L. Kelts, Tristan H. Nielson, Ibiere Lovelyn Epelle, Nicodemus C. Monear, Miguel T. G. Strawn, Benjamin N. Woerner, Besa Xhabija · 2022 · BioChem
46. Broad Spectrum Antiviral Therapy can Supersede Vaccination Strategy for Combating COVID-19 Pandemic
    Ashok K. Chakraborty · 2021 · Medical Journal of Clinical Trials & Case Studies
47. Airport Personnel and Coronavirus Disease-2019: A Seroprevalence Study in Taiwan
    Chien‐Chang Lee, Chih‐Hung Wang, Shih-Tien Hsu, Shih‐Hung Liu, Tse-Hua Lo, Yen-Hsing Liu, Alexa Papaila, Shan‐Chwen Chang · 2022 · Emergency Medicine - Open Journal
48. Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an academic medical centre in Austria
    Martin Riesenhuber, Christian Nitsche, Christoph J. Binder, Eva S. Schernhammer, Tanja Stamm, Friedrich Jakse, Elaaha Anwari, Fardin Hamidi, Helmuth Haslacher, Thomas Perkmann et al. · 2023 · BMJ Open
49. Understanding the SARS-CoV-2 Virus Neutralizing Antibody Response: Lessons to Be Learned from HIV and Respiratory Syncytial Virus
    Nigel J. Dimmock, Andrew J. Easton · 2023 · Viruses
50. Presence of neutralizing SARS‐CoV‐2 antibodies in asymptomatic population of N'Djamena, Chad
    Andrillene Laure Deutou Wondeu, Mahamat Fayiz Abakar, Federica Frasca, Zita Aleyo Nodjikouambaye, Fatima Abdelrazak Zakaria, Nathan Naïbeï, Guy R. Takoudjou Dzomo, Djallaye Djimtoïbaye, Joseph Mad-Toïngué, Carolina Scagnolari et al. · 2024 · Immunity Inflammation and Disease
51. Adaptive Cellular Responses following SARS-CoV-2 Vaccination in Primary Antibody Deficiency Patients
    Sudhir Gupta, Houfen Su, Sudhanshu Agrawal, Yeşim Yılmaz Demirdağ, Michelle Tran, Sastry V. S. Gollapudi · 2024 · Pathogens
52. SARS-CoV-2 infections before, during, and after the Omicron wave: a 2-year Indian community cohort study
    Ramya Madhavan, Jackwin Sam Paul, Sudhir Babji, Isai Thamizh, Dilesh Kumar, Shainey Alokit Khakha, Aarene Rennie, Keerthana Kumar, Pavithra Dhanapal, Poornima Saravanan et al. · 2024 · The Lancet Regional Health - Southeast Asia
53. SARS-CoV-2 IgG Seroprevalence in the Okinawa Main Island and Remote Islands in Okinawa, Japan, 2020–2021
    Yoshihiro Takayama, Yusuke Shimakawa, Yoshiaki Aizawa, Christian Butcher, Naomi Chibana, Mary K. Collins, Kohei Kamegai, Tae Gyun Kim, Satoshi Koyama, Ryota Matsuyama et al. · 2024 · Japanese Journal of Infectious Diseases
54. In-silico evaluation of the T-cell based immune response against SARS-CoV-2 omicron variants
    Shivangi Sharma, Diya Roy, Sarah Cherian · 2024 · Scientific Reports
55. Durability of Functional SARS‐CoV‐2‐Specific Immunological Memory and T Cell Response up to 8–9 Months Postrecovery From COVID‐19
    Diptee Trimbake, Dharmendra Singh, Y. K., Prasad Babar, Varsha Dange, Anuradha S. Tripathy · 2025 · Journal of Immunology Research
56. Sustained Positivity and Reinfection With SARS-CoV-2 in Children: Does Quarantine/Isolation Period Need Reconsideration in a Pediatric Population?
    Anjali Patwardhan · 2020 · Cureus
57. Long-term antibody-response monitoring following primary exposure to SARS-COV-2 and afterward mRNA COVID-19 vaccination: A case report
    Bela Balint, Milena Todorović, Zorana Andrić, Milica J. Jovicic, Glorija Blagojevic, Miodrag J Čolić · 2021 · Vojnosanitetski pregled
58. A Review of the Animal and Human Trials of the Ad5-nCoV Vaccine Candidate
    Cheng En Xi, Jasrita Singh · 2021 · Journal of Student Research
59. Immune Responses in Patients with COVID-19: An Overview
    Deepak Kamat, Aarti Kamat, Ambika Mathur · 2021 · Pediatric Annals
60. Особенности гуморального иммунного ответа при коронавирусной болезни (COVID-19)
    О.М. Зінчук, A.V. Petrukh, N.I. Hrynchyshyn, К.К. Shvaievska · 2021 · ACTUAL INFECTOLOGY
61. Диагностическая значимость выявления нейтрализующих антител к SARS-CoV-2
    H.L. Kyseliova, Kseniia Voronova, V.M. Isaiev · 2021 · ACTUAL INFECTOLOGY
62. Uninformative and unuseful: why it is necessary to actively challenge COVID-19 antibody testing postvaccination
    Daniel Romero-Álvarez, Daniel F. López‐Cevallos, Irene Torres · 2021 · Public Health
63. Defining Antibody Seroprevalence and Duration of Humoral Responses to SARS-CoV-2 Infection and/or Vaccination in a Greek Community
    Ourania S. Kotsiou, Dimitrios Papagiannis, Εvangelos C. Fradelos, Dimitra S. Siachpazidou, Garyfallia Perlepe, Angeliki Miziou, Athanasios P. Kyritsis, George D. Vavougios, Georgios Kalantzis, Konstantinos I. Gourgoulianis · 2021 · International Journal of Environmental Research and Public Health
64. Socio-demographic Heterogeneity in Prevalence of SARS-COV-2 Infection and Death Rate: Relevance to Black College Student Knowledge of COVID-19 and SARS-COV-2
    Jahangir Emrani, Elia Nichelle Hefner · 2022 · Journal of Racial and Ethnic Health Disparities
65. Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
    Farah M. Shurrab, Duaa W. Al‐Sadeq, Haissam Abou-Saleh, Nader Izz Eddin Al-Dewik, Amira E. Elsharafi, Fatima M. Hamaydeh, Bushra Y. Abo Halawa, Tala M. Jamaleddin, Huda M. Abdul Hameed, Parveen Banu Nizamuddin et al. · 2022 · Vaccines
66. Improved immunogenicity following the third dose of BNT162b2 mRNA vaccine in heart transplant recipients
    Aviv A. Shaul, Osnat Itzhaki Ben Zadok, Binyamin Ben‐Avraham, Vicky Yaari, Alon Barsheshet, Amos Levi, Haim Ben Zvi, Noa Eliakim Raz, Galia Abed, Miriam Abuhazira et al. · 2022 · European Journal of Cardio-Thoracic Surgery
67. Isotyping and quantitation of the humoral immune response to SARS-CoV-2
    Krystal A Goyins, Jieh‐Juen Yu, Sara B. Papp, Rachel L. Beddard, Ashlesh Krishna Murthy, James P. Chambers, Bernard P. Arulanandam · 2022 · Experimental Biology and Medicine
68. Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment
    Jinyong Kim, Euijin Chang, Song Yi Park, Dae‐Won Lee, Chang Kyung Kang, Pyoeng Gyun Choe, Nam Joong Kim, Myoung‐don Oh, Wan Beom Park, Kyung-Hun Lee et al. · 2022 · The Oncologist
69. In Vitro Diagnostic Assay to Detect SARS-CoV-2-Neutralizing Antibody in Patient Sera Using Engineered ACE-2 Mini-Protein
    Bruna Andersen Pereira de Jesus, Anderson Gomes, Alex E. Clark, Tayse Andrade Rodrigues, Melissa M. Ledgerwood-Lee, Westley Van Zant, Howard Brickner, Meiqiao Wang, David L Blum, María B. Cassera et al. · 2022 · Viruses
70. Immunological Findings in a Group of Individuals Who Were Poor or Non-Responders to Standard Two-Dose SARS-CoV-2 Vaccines
    Qiang Zeng, Xue Yan Yang, Qi Gao, Yongzhe Li, Yong-zhe Li, Gang Huang, Yang Xu · 2023 · Vaccines
71. In vitro neutralizing activity of BNT162b2 mRNA‐induced antibodies against full B.1.351 SARS‐CoV‐2 variant
    Esther Serrano‐Conde, Alba Leyva, Ana Paula Fuentes, Adolfo de Salazar, Natalia Chueca, Sonia Pérez‐Castro, Benito José Regueiro, Almudena Rojas, Joaquín Mendoza, Jose Rojas et al. · 2021 · Transboundary and Emerging Diseases
72. RapidQ: A reader-free microfluidic platform for the quantitation of antibodies against the SARS-CoV-2 spike protein
    Juha‐Pekka Mattila, Arlene Amaro, Monica Longo, James F. Antaki, Sanam Koirala, Alberto Gandini · 2022 · Biomicrofluidics
73. Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria
    Heike Rebholz, Ralf J. Braun, Titas Saha, Oliver Harzer, Miriam Schneider, Dennis Ladage · 2022 · PLoS ONE
74. Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers
    Mónika Korodi, István Horváth, Kinga Rákosi, Zsuzsanna A. Jenei, Gabriella Hudák, Melinda Kákes, Katalin Dallos-Fejér, Enikő Simai, Orsolya Páll, Natalia Staver et al. · 2022 · Vaccine
75. Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) Serology in the Vaccination Era and Post Booster Vaccination
    Latha Dulipsingh, Maxine Lang, Margaret R. Diffenderfer, Lisa Cook, Jennifer Puff, Lynn Diaz, Lihong He, Ernst J. Schaefer · 2022 · Journal of Clinical Virology Plus
76. A COVID–19-fertőzés és a védőoltások hatásosságának vizsgálata egészségügyi dolgozókon
    Bernadette Rojkovich, Dóra Németh, Elek Dinya, Erzsébet Nagy, Eszter Török, Imre Lázár, András Perduk, Pál Géher, György Nagy · 2023 · Orvosi Hetilap
77. Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days
    Amanda Haymond, Abdulla A Damluji, Aarthi Narayanan, Claudius Mueller, A. Reeder, Farhang Alem, G. Maxwell, E. Petricoin, L. Liotta, C. Defilippi · 2021 · Journal of Infectious Diseases
78. Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans
    Michael E. Watson, Kengo Inagaki, Jason B. Weinberg · 2021 · Comparative Medicine
79. Evolution of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence among employees of a US academic children’s hospital during coronavirus disease 2019 (COVID-19) pandemic
    Brian T. Fisher, Anna P. Sharova, Craig L K Boge, Sigrid Gouma, Audrey Kamrin, Jesse A. Blumenstock, Sydney Shuster, Lauren Gianchetti, Danielle Collins, Elikplim H. Akaho et al. · 2021 · Infection Control and Hospital Epidemiology
80. Longevity of seropositivity and neutralizing titers among SARS-CoV-2 infected individuals after 4 months from baseline: a population-based study in the province of Trento
    P. Stefanelli, A. Bella, G. Fedele, S. Fiore, S. Pancheri, E. Benedetti, C. Fabiani, P. Leone, P. Vacca, Ilaria Schiavoni et al. · 2020 · medRxiv
81. WITHDRAWN
    Shoumen Datta · 2021 · ChemRxiv
82. Analytical and diagnostic performances of a high-throughput immunoassay for SARS-CoV-2 IgM and IgG
    Andrea Padoan, Chiara Cosma, Paolo Zaupa, Mario Plebani · 2020 · medRxiv
83. Persisting adaptive immunity to SARS-CoV-2 in Lower Austria
    Dennis Ladage, Oliver Harzer, Peter A. Engel, Hannes Winkler, Ralf J. Braun · 2021 · medRxiv
84. Estimation of Total Immunity to SARS-CoV-2 in Texas
    Stacia M. DeSantis, Luis León‐Novelo, Michael D. Swartz, Ashraf S. Yaseen, Melissa A. Valerio, Frances A. Brito, Jessica A. Ross, Harold Willis Kohl, Sarah Elizabeth Messiah, Steve H. Kelder et al. · 2021 · medRxiv
85. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2
    Runhong Zhou, Na Liu, Xin Li, Qiaoli Peng, Cheuk-Kwan Yiu, Haode Huang, Dawei Yang, Zhenglong Du, Hauyee Kwok, Ka‐Kit Au et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
86. Characterization of SARS-CoV-2 Convalescent Patients’ Serological Repertoire Reveals High Prevalence of Iso–RBD Antibodies
    Nicholas C. Curtis, Seungmin Shin, Andrew P. Hederman, Ruth I. Connor, Wendy Wieland‐Alter, Steven Ionov, Jennifer A. Boylston, Josh Rose, Mrunal Sakharkar, Dana B. Dorman et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
87. COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects
    Shen Wang, Ling Li, Fei-Hu Yan, Yu-Wei Gao, Song-Tao Yang, X. Xia · 2021 · Vaccines
88. Coronavirus Vaccines
    Stanley M. Perlman, Mark R. Denison · 2023 · Elsevier eBooks
89. Contribution of the 2021 COVID-19 vaccination regime to COVID-19 transmission and control in South Africa: A mathematical modeling perspective
    Tesfalem Abate Tegegn, Yibeltal Adane Terefe · 2025 · Chaos Solitons & Fractals
90. The Protective Effect of Serum Levels of Vitamins C, D, and E and IgG and IgM Antibodies in Individuals Vaccinated Against COVID-19 and Experienced Disease Relapse
    Ashkan Alamdary, Alireaza Gholami, Maryam Shahali, Delaram Doroud, Rasul Moukhah, Mohammad Javad Hossein Tehrani, Rajab Mardani, Nayebali Ahmadi · 2024 · Jundishapur Journal of Microbiology
91. Salivary immune responses after COVID-19 vaccination
    Kenny Nguyen, Boris Relja, Monica Epperson, Sohee Park, Natalie J. Thornburg, Verónica Costantini, Jan Vinjé · 2024 · PLoS ONE
92. SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023
    Marjut Sarjomaa, Kristine Karlsrud Berg, Keson Jaioun, Yngvar Tveten, Hege Kersten, Harald Reiso, Randi Eikeland, Carina Thilesen, Svein Arne Nordbø, Ingeborg Sundsvalen Aaberge et al. · 2025 · BMC Medicine
93. SARS-CoV-2 antibody dynamics among kidney transplant recipients 3 months after BNT162b2 vaccination: a prospective cohort study
    Dana Yelin, Benaya Rozen‐Zvi, Dafna Yahav, Naomi Ben-Dor, Tali Steinmetz, Timna Agur, Boris V. Zingerman, Shira Schneider, Shelly Lichtenberg, Haim Ben‐Zvi et al. · 2022 · Clinical Kidney Journal
94. Low-entry-barrier point-of-care testing of anti-SARS-CoV-2 IgG in the population of Upper Austria from December 2020 until April 2021—a feasible surveillance strategy for post-pandemic monitoring?
    Christian Doppler, Michael Feischl, Clara Ganhör, Špela Puh, Marina Müller, Michaela Kotnik, Teresa Mimler, Max Sonnleitner, David Bernhard, Christian Wechselberger · 2022 · Analytical and Bioanalytical Chemistry
95. Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population
    Dorine Decarreaux, Julie Sevila, Shirley Masse, Lisandru Capai, Toscane Fourié, Paola Mariela Saba Villarroel, Abdennour Amroun, Elif Nurtop, Matthieu Vareille, Thierry Blanchon et al. · 2022 · International Journal of Environmental Research and Public Health
96. Features of the Formation of Seroprevalence to SARS-CoV2 in the Population of the Republic of Tatarstan during the Spread of COVID-19
    И. Д. Решетникова, Elena V. Agafonova, Niyaz M. Khakimov, Yu. A. Tyurin, Н.Д. Шайхразиева, V. B. Ziatdinov · 2023 · Epidemiology and Vaccinal Prevention
97. SARS-CoV-2 seroconversion in children attending daycare versus adults in Germany between October 2020 and June 2021
    Ulrike Kubisch, Anna Sandoni, Juliane Wurm, Anja Schienkiewitz, Martin Schlaud, Tim Kuttig, Bianca Finkel, Susanne Jordan, Julika Loss · 2023 · Communications Medicine
98. Neutralizing antibodies from naturally infected individuals against SARS-CoV-2 Gamma and Delta variants in the Paraguayan population
    Angélica Samudio, Pablo H. Sotelo, Pamela González-Maldonado, Laura Alfonso, Fernando Valiente‐Echeverría, Ricardo Soto‐Rifo, Patricia Langjahr · 2023 · The Journal of Infection in Developing Countries
99. Seroprevalence of SARS-CoV-2 antibodies among healthcare workers in Dutch hospitals after the 2020 first wave: a multicentre cross-sectional study with prospective follow-up
    Claudia Recanatini, Corine H. GeurtsvanKessel, Suzan D. Pas, Els M. Broens, Martje L. Maas, Rosa van Mansfeld, Anne Mutsaers-van Oudheusden, Miranda van Rijen, Emile F. Schippers, Arjan Stegeman et al. · 2023 · Antimicrobial Resistance and Infection Control
100. Flow Cytometry-Based Measurement of Antibodies Specific for Cell Surface-Expressed Folded SARS-CoV-2 Receptor-Binding Domains
     Al Nasar Ahmed Sehgal, Jera Safran, Bernhard Kratzer, Pia Gattinger, Robert B. Stieger, Laszlo Musiejovsky, Doris Trapin, Paul Ettel, Ulrike Körmöczi, Arno Rottal et al. · 2024 · Vaccines